Clinical trials show that the area under the inhibitory curve (AUIC) is predictive of antibacterial killing rates in patients with nosocomial pneumonia and is useful for predicting clinical or microbiological outcomes and making dosage adjustments with b-lactams, quinolones, aminoglycosides, and vancomycin. The AUIC values of two antibiotics are additive, and since antibiotics are often given in combination, determining the AUIC for antibiotic combinations could potentially predict the microbiological outcomes for patients given these combinations. To further address this question, mathematical modeling was used to study in vitro pharmacokinetic and pharmacodynamic interactions of the antimicrobials piperacillin and ciprofloxacin. These agents were also studied in vivo in healthy volunteers. Blood samples were obtained for analysis of serum drug concentrations, and serum inhibitory titers were determined against eight common bacterial pathogens, chosen to reflect the range of MIC values to ciprofloxacin and piperacillin. Additive AUIC relationships predictive of bacterial killing rates were typical in patients given these antibiotics in combination. to an AUIC over 24 hours (AUIC 24 ) of 125 [15]. As the MIC ensuring a broad spectrum of activity. Double b-lactam combirises and therefore coverage becomes õ80% of AUC above nations have also been studied but are not optimal as combina-MIC, the resulting AUIC values fall further and further below tion treatment regimens for seriously ill patients [4]. The poten-125, which is a correlate of clinical and microbiological failure tial for nephrotoxicity and ototoxicity from aminoglycosides [14 -19] and microbial resistance [20, 21] . has caused some clinicians to evaluate new possibilities such as As we developed these models, the outcome measure for combinations of fluoroquinolones and b-lactam agents. These correlation with the pharmacokinetic/pharmacodynamic (PK/ combinations have shown promising results in small clinical PD) parameters was usually bacterial eradication, for several trials [5 -9, 10].
Clinical trials show that the area under the inhibitory curve (AUIC) is predictive of antibacterial killing rates in patients with nosocomial pneumonia and is useful for predicting clinical or microbiological outcomes and making dosage adjustments with b-lactams, quinolones, aminoglycosides, and vancomycin. The AUIC values of two antibiotics are additive, and since antibiotics are often given in combination, determining the AUIC for antibiotic combinations could potentially predict the microbiological outcomes for patients given these combinations. To further address this question, mathematical modeling was used to study in vitro pharmacokinetic and pharmacodynamic interactions of the antimicrobials piperacillin and ciprofloxacin. These agents were also studied in vivo in healthy volunteers. Blood samples were obtained for analysis of serum drug concentrations, and serum inhibitory titers were determined against eight common bacterial pathogens, chosen to reflect the range of MIC values to ciprofloxacin and piperacillin. Additive AUIC relationships predictive of bacterial killing rates were typical in patients given these antibiotics in combination.
Combinations of b-lactam antibiotics with aminoglycosides [11 -17] . The typical optimized relationship between antibiotic have been used extensively in the treatment of serious infecserum profile, as the area under the curve (AUC) and MIC, is tions. Such combinations have generally been superior to moillustrated in figure 1. notherapy with b-lactam agents in important subpopulations, For any antibiotic given at dosing intervals of 3 -4 halfincluding patients with endocarditis [1] , gram-negative sepsis lives, there is general concordance between 80% of the AUC [2], and pseudomonas bacteremia [3] . Although not always above the MIC of the organism and an area under the inhibitory demonstrated to be superior, combination therapy is commonly curve (AUIC) of 125. For this reason, calculations of AUC used empirically for treatment of gram-negative pneumonia and the AUC/MIC relationships in figure 1 would correspond and other nosocomial infections, with the additional goal of to an AUIC over 24 hours (AUIC 24 ) of 125 [15] . As the MIC ensuring a broad spectrum of activity. Double b-lactam combirises and therefore coverage becomes õ80% of AUC above nations have also been studied but are not optimal as combina-MIC, the resulting AUIC values fall further and further below tion treatment regimens for seriously ill patients [4] . The poten-125, which is a correlate of clinical and microbiological failure tial for nephrotoxicity and ototoxicity from aminoglycosides [14 -19] and microbial resistance [20, 21] . has caused some clinicians to evaluate new possibilities such as As we developed these models, the outcome measure for combinations of fluoroquinolones and b-lactam agents. These correlation with the pharmacokinetic/pharmacodynamic (PK/ combinations have shown promising results in small clinical PD) parameters was usually bacterial eradication, for several trials [5 -9, 10] .
reasons. (1) Bacterial eradication is a better marker for the One of the first goals in the development of antibiotic dosing action of an antibiotic, since in vitro and animal model studies strategies is to develop a method that can effectively describe demonstrate more consistent concentration relationships with the relationship between pharmacokinetics, pharmacodynamreductions in the infection-site colony counts than with clinical ics, MIC, and bacterial outcomes for single antibiotic therapy. cure, survival, or success vs. failure [22, 23] . (2) Animal model We have conducted a number of studies of patients with nosostudies [22, 23] infection bacterial survival vs. time [19] . Typical of concentraClinical Infectious Diseases 1998;27:40-6 tion-dependent action, there were multiple statistically signifi- extubated earlier and discharged earlier from the intensive care ship. The most important was the group with AUIC õ 125, in unit [24] . which treatment failed for 70%. Multiple breakpoints are typiFor antibiotics with concentration-independent bacterial killcal for the antibiotics with concentration-dependent killing ing rates, like the cephalosporins [12, 16, 25] and vancomycin rates, such as fluoroquinolones and aminoglycosides. Clearly, [17] , there are only two statistically significantly different more rapid bacterial eradication can be achieved with higher AUIC breakpoints: ú125 and õ125 (P õ .01). Typical data AUIC values.
on AUIC vs. bacterial eradication times are shown in figure 3 On the basis of these data, we have argued for an AUIC for ceftazidime and cefmenoxime, two third-generation cephabreakpoint of §250 for ciprofloxacin [19] . Obviously, for relalosporins with time-dependent bacterial killing. The format is tively nontoxic drugs like the fluoroquinolones, there is an the same as in figure 2, but with the cephalosporins there is advantage to raising doses to achieve more rapid bacterial killno evident improvement in the rate of bacterial killing as the ing, especially in cases of lower respiratory tract infection, if AUIC becomes higher and higher above 125. Indeed, the maxiit can be shown that care will be less expensive for patients mum AUIC in figure 3 approached 10,000, yet there were no bacteria eradicated at 24 hours into therapy. These results confirm that both time above MIC and the AUIC are predictive of bacteriologic outcome for these timedependent-killing antibiotics. Both parameters are useful, because an AUIC of 125 approximates 80% of time above MIC, as well as 80% of the AUC above MIC. There is strong concordance between the two parameters whenever dosing intervals are õ4 half-lives. Obviously, as intervals between doses become quite long, the concordance will disappear. Thus, it is necessary to limit dosing intervals to within 3 -4 half-lives if the correlation is to be maintained.
When dosing intervals are reasonable within these guidelines (i.e., õ4 half-lives of the antibiotic in question), adequate time above MIC is ensured and the AUIC is predictive of bacteriologic outcomes. In contrast, when dosing intervals vary widely, and especially when intervals are long for the relatively short- crobials. Synergy determined by either the checkerboard or time-kill method has not been shown to correlate consistently with improved clinical outcome. Moreover, there is lack of and included 12 healthy subjects (6 males and 6 females). The concordance between these two in vitro methods [29 -31] , persubjects received each of the following treatments iv at weekly haps because of problems inherent in the checkerboard methods intervals: 4.0 g of piperacillin over 30 minutes, 400 mg of [29] . It is also likely that in vitro study design has not often ciprofloxacin over 1 hour, and 400 mg of ciprofloxacin over 1 been optimized to test these principles rigorously.
hour plus 4.0 g of piperacillin over 30 minutes. Serum drug Serum cidal activity has also been used to assess the activity concentrations for ciprofloxacin and piperacillin were deterof antibiotic combinations [32, 33] , thereby ensuring that clinimined by means of high-pressure liquid chromatography methcally relevant concentrations are evaluated. Antimicrobial acods that were developed and validated at this laboratory. tivity has also been assessed with use of the area under the There were eight test organisms, including two strains each bactericidal time curve [34] . Our laboratory has extended these of Pseudomonas aeruginosa, Staphylococcus aureus, Klebmethods to serum inhibitory titers and serum ultrafiltrate titers siella pneumoniae, and Enterobacter cloacae. Serum ultrafil- [35] . From these investigations, there is evidence that AUIC trate inhibitory testing was performed as described by Leggett can predict microbiological and clinical cure rates [15 -17] . et al. [37] . The individual pharmacokinetic parameters for each The challenge is to use the AUIC method effectively to drug were estimated with use of ADAPT II (Biomedical Simucharacterize combination therapy as well as it has done with lations Resource, Los Angeles) and the MAP Bayesian algosingle agents. Theoretically, AUIC values would be additive, rithm. Model discrimination was accomplished with use of and the effect of additivity would be characterized as bacterial Akaike's information criterion [38] . Statistical comparisons killing in vivo in direct relationship to the sum of two AUIC were made with the Systat software package (Systat, Evansvalues (in the case of two antibiotics). Obviously, any bacterial ton, IL). eradication that occurs more rapidly than would be predicted
The MIC and AUIC 24 values calculated for each organism by the sum of the two AUIC values could meet criteria for are shown in table 1. These values are derived from the pharmasynergy. Antibacterial killing rates that occur more slowly than cokinetic parameters in table 2 [36] . A good mix of organisms predicted would potentially indicate antagonism. These additivwas chosen for this study, in that some of the bacteria were ity principles can be tested quite readily in our patients with more susceptible to ciprofloxacin or piperacillin, some were nosocomial pneumonia.
susceptible to both approximately equally, and some were relatively unsusceptible to both, clearly justifying combination therapy. Pseudomonas typically is the latter: against this organVolunteer Model ism, MIC values of both antibiotics are on the high end (taIn order to evaluate these relationships in advance of studies ble 1). of patients, we have developed a pharmacodynamic model to
In theory, a measured serum inhibitory titer can be predicted evaluate antimicrobial interactions in healthy volunteers given from the drug concentration as the AUIC 24 and the bacterial single and combination antimicrobials. This method allows as-MIC. Figure 4 shows the relationship between measured insessment of combination antimicrobial activity and interactions verse serum ultrafiltrate inhibitory titers and the predicted sefrom clinically relevant concentrations. This study utilized serum inhibitory titer. The calculation of predicted serum activity rial serum ultrafiltrate inhibitory titers along with pharmacodywas adjusted 16% for protein binding of ciprofloxacin and namic modeling to address the interaction between ciprofloxapiperacillin [39, 40] . This figure demonstrates concordance between the measured and predicted serum activity. cin and piperacillin. The study [ [40, 41] ; however, concomitant administration of piperacillin caused a statistically significant reduction of Enterobacteriaceae and P. aeruginosa, checkerboard studies of ciprofloxacin plus piperacillin revealed an additive interacin the clearance and steady state volume of distribution of ciprofloxacin [36] . A similar interaction has been reported with tion for ú99% of the isolates [43] . Among 108 clinical isolates of P. aeruginosa, synergy was demonstrated by the checkerthe combination of ciprofloxacin and azlocillin [42, 43] . As b-lactams and quinolones are both secreted in the proximal board method for §50% of isolates that were resistant to ciprofloxacin (MIC, ú2 mg/mL) but susceptible to a b-lactam. tubule, the mechanism is probably a competition for active transport. The predominance of the effect on ciprofloxacin is However, among quinolone-susceptible, b-lactam-resistant organisms, synergy was demonstrated in £10%. Among organprobably a consequence of the higher molar concentration of piperacillin present in the proximal renal tubule.
isms that were susceptible to both drugs, synergy occurred at a rate of £20% [44] . No antagonism was seen. CiprofloxacinThe MICs for monotherapy with ciprofloxacin and piperacillin showed ciprofloxacin to be more potent than piperacillin.
resistant isolates (MIC 90 , 4 mg/mL) showed synergy between ciprofloxacin and piperacillin at a rate of 21%; however, Consistent with lower MIC values, ciprofloxacin showed greatest activity against Klebsiella and Enterobacter and lesser acthe MIC 90 of piperacillin was not stated [45] . In another study (piperacillin MIC 90 , 256 mg/mL; ciprofloxacin MIC 90 , 1 tivity against Pseudomonas and Staphylococcus organisms. Piperacillin showed greatest activity against Pseudomonas and mg/mL), synergy occurred at a rate of 12.5%, and no antagonism was noted [46] . Klebsiella organisms and least activity against Enterobacter. The pharmacodynamic interaction was additive for the combination of piperacillin and ciprofloxacin [36] .
Discussion
Clinical and microbiological outcomes after therapy with single agents are becoming considerably more predictable now that studies are emerging that correlate microbial, clinical, or microbiological outcomes with PK/PD parameters like the time above MIC, peak-to-MIC ratio, and AUIC. However, the same level of predictability is definitely not afforded by antimicrobial combination regimens, even though the use of single-agent regimens is uncommon for seriously ill patients in critical care units.
Anxiety with regard to the PK/PD of combination regimens is lessened if (1) one assumes additivity occurs in most cases of antibiotic interaction (which is likely to be true, given the that the AUIC is the only additive parameter of the available / 9c51$$jy31 06-16-98 14:08:27 cida UC: CID Our in vitro experiments used more rigorous methods [29] ing support to this mode of describing the action of antibiotics in combination. than employed by the checkerboard model and demonstrated additivity between ciprofloxacin and piperacillin for the eight
The combination of ciprofloxacin and piperacillin has the greatest potential for measurable benefit when the AUIC proorganisms tested. For some of the organisms, there were a few isolated cases in the ''possible synergy'' and ''possible vided by ciprofloxacin alone is inadequate. This occurred with the P. aeruginosa strain 1 and S. aureus strain A listed in table antagonism'' range. In subsequent studies, this variability has been reduced by more intensive prior characterization of the 1. Organisms such as Serratia marcescens and P. aeruginosa for which the MICs of ciprofloxacin are ú0.5 mg/mL are often MICs. In the current study, none of the test organisms exhibited resistance to ciprofloxacin. Thus, it is unknown whether synincluded in this category. The combination of ciprofloxacin and piperacillin, although additive, would boost the total AUIC ergy would be shown in the circumstance of quinolone resistance and b-lactam susceptibility, as was shown in the in vitro to values above 125, which are associated with better outcome. An interesting situation is evolving with P. aeruginosa and study mentioned previously [44] .
A few clinical trials involving febrile neutropenic patients piperacillin/tazobactam. It appears that a small proportion of P. aeruginosa strains are more susceptible to piperacillin/tazohave been conducted to evaluate the combination of a quinolone and a b-lactam agent [5 -9] . Four randomized trials combactam than to piperacillin alone [48] . Our work [49] confirms that this in vitro advantage can translate into substantial inpared ciprofloxacin/azlocillin to a b-lactam/aminoglycoside combination [5 -7, 9]. These small trials showed similar recreases in AUIC for ciprofloxacin in combination with piperacillin/tazobactam, compared with AUICs for ciprofloxacin sponse rates between the two treatment groups and suggested that a quinolone/b-lactam combination was as efficacious as a combined with piperacillin alone [36, 49] . This situation is yet another example of how AUIC values, determined from the b-lactam/aminoglycoside regimen.
In a noncomparative trial of ciprofloxacin/piperacillin calculated or measured AUC and the MIC, can aid evaluations of combination therapy regimens, bridging the gap between used in 47 episodes of febrile neutropenia (41 patients), an overall success rate of 61% was noted [8] . This study and studies in vitro, in animal models, and in the patient care setting. another, larger trial [47] employed a low dose of ciprofloxacin (200 mg twice daily), which has been shown to be subopEmpirical therapy does not always require multiple combinations of the most expensive broad-spectrum agents in our armatimal as monotherapy [19, 47] . Area under the inhibitoryactivity-vs.-time curve (AUC/MIC) has been shown to corrementarium. The methods described here can help to make the distinction. When combinations are required, the AUIC values late with clinical and microbiological outcome and with time to bacterial eradication for ciprofloxacin and cefmenoxime can promote selection of the best combination and calculation of the optimal dose. In this manner, the AUIC is a strong [16, 19] .
There are many situations in which AUC/MIC cannot be adjunct to the desired positive clinical outcome. optimized with monotherapy because dose limits would be exceeded. In these situations, combination therapy is warranted. This concept was employed in a clinical study [10] in which calculation of the target, AUIC was assumed to be additive for interaction [29] , there are more cases of additive interaction 
